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Aims: Several lines of evidence support the hypotheses that the oxidation of low density lipoprotein (LDL)
may play a crucial role in the initiation and progression of atherosclerosis. Oxidative stress is one of the causes
of the overproduction of reactive species that increase the formation of oxidized LDL. Thiosemicarbazones are
compounds used in anticancer, antiviral and antifungal therapy; however, its redox activity has been
controversial. Thus, we tested, in vitro, a possible antioxidant activity of a thiosemicarbazone derivate, the
isatin-3-N4-benzilthiosemicarbazone (IBTC).
Main methods: We measured the conjugated diene formation in serum and LDL as well as the loss of
tryptophan ﬂuorescence in LDL induced by two oxidant agents, 2,2-azobis(2-amidinopropane dihydrochlor-
ide) (AAPH) and Cu2+. Thiobarbituric acid reactive substances (TBARS) formation in LDL and in different rat
tissues was also assessed. The toxicity of IBTC was measured using aortic slices viability assay.
Key ﬁndings: Our results show that IBTC signiﬁcantly reduced the AAPH and Cu2+-induced formation of
conjugated dienes, increased in a dose-dependent manner the lag phase and the t1/2 of tryptophan
ﬂuorescence, and reduced the TBARS formation in LDL, plasma and rat tissues, showing no toxicity to aortic
slices.
Signiﬁcance: These results indicate that IBTC is a good antioxidant and a promising antiatherogenic agent for
further studies in vivo.
© 2011 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Cardiovascular disease (CVD) is the leading cause of death in
developed countries (Hennekens et al., 1997). Atherosclerosis is a
response of blood vessels to injury at the beginning of the formation of
an atherosclerotic plaque (Li, 2005; Tracy, 1998). Low-density
lipoprotein (LDL) is a major cholesterol carrier in the bloodstream,
and the concentration of LDL-cholesterol is directly correlated with
the incidence of CVD (Austin et al., 1988; Campos et al., 1992).
Numerous studies have revealed that increased oxidized LDL (oxLDL)
acts as an atherogenic factor by triggering an inﬂammatory process.
OxLDL can induce cell activation, secretion of inﬂammatory media-
tors, and expression of adhesion molecules (Witztum and Steinberg,
1991), that culminates with leukocyte accumulation in the sub-
endothelial space. Notably, recruited inﬂammatory cells can enhance
the formation of oxLDL. Once in the intima, monocytes become tissue
macrophages, which can internalize oxLDL (Libby, 2002). This leadsa, CCNE, Universidade Federal
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sevier OA license.to the formation of foam cells (hallmark of early atherogenesis)
(Parthasarathy et al., 1986). Furthermore, oxLDL has been shown to
enhance atherogenesis by other mechanisms, such as cytotoxicity and
stimulation of thrombotic and inﬂammatory events (Witztum, 1993).
Remarkably, oxidative stress plays an important role in the patho-
genesis and/or progression of CVD (Dhalla et al., 2000). Intracellular
components can be damaged by reactive species (RS) generation
(Augusto et al., 2002). To remove RS, cells display several enzymatic
and non-enzymatic protection and repair mechanisms (Halliwell,
2006). Several pathological conditions can be associated with an
increase in RS production that surpasses the coping capacity of the
cellular antioxidant system (Büyükokuroglu, 2008; Gutteridge and
Halliwell, 1994).
Thiosemicarbazones are well-known metal chelators and their
biological activities have been attributed to their ability to form bio-
logically active complexes (Kalinowski and Richardson, 2005). Thiose-
micarbazones have received considerable interest in research; ﬁrstly,
due to their wide pharmacological utility (Beraldo and Gambino, 2004;
Sartorelli et al., 1971). Secondly, their versatility as ligands allows them
to generate a great variety of coordinationmodes (Pandeya et al., 1999;
Pedrido et al., 2008). Moreover, thiosemicarbazone metal complexes
have also been investigated as radical scavengers (Wada et al., 1994).
21R.P. Barcelos et al. / Life Sciences 89 (2011) 20–28However, their redox properties have been controversial; some studies
report them to be antioxidant compounds (Ghosh et al., 2009;
Hrnciarová et al., 1998) while other studies report them to be oxidative
compounds (Byrnes et al., 1990; Karatas et al., 2006).
A possible method to prevent atherosclerotic diseases would be
through the administration of antioxidants (de Lima Portella et al.,
2008). However, there is some controversy regarding the usefulness of
antioxidant therapy for the prevention of atherosclerosis (Mashima
et al., 2001), and this reﬂects our limited understanding of the thera-
peutic use of antioxidants and the need for further studies. To the best
of our knowledge, there is little research on the redox activity of
thiosemicarbazones, and therefore, their potential as antioxidants
must be explored. Thus, this studywas conducted to test the thiosemi-
carbazone isatin-3-N4-benzilthiosemicarbazone (IBTC) in vitro and
ex vivo in order to determine if IBTC might be useful against LDL oxi-
dation and represent a possible therapeutic drug for testing in future
atherosclerosis studies.Materials and methods
Synthesis of isatin-3-N4-benzilthiosemicarbazone
The synthesis of isatin-3-N4-benzilthiosemicarbazone (IBTC) is
described by (Fonseca et al., 2010). The chemical structure of IBTC is
shown in Fig. 1.Animals
Adult Wistar rats (200–250 g) were obtained from the Federal
University of Santa Maria and maintained in an air conditioned room
(20–25 °C) under natural lighting conditions with water and food ad
libitum. All the experimental procedures performed were conducted
according to the guidelines of the Committee on Care and Use of
Experimental Animal Resources of the Federal University of Santa
Maria, Brazil.LDL isolation
LDL was isolated from fresh human plasma by discontinuous
density-gradient ultracentrifugation as described by Luiz da Silva et al.
(1998), with few modiﬁcations. Brieﬂy, plasma of non-fasted healthy
normolipidemic voluntary donors was collected and pooled with EDTA
(1 mg/mL). Sucrose (ﬁnal concentration, 0.5%) was added to prevent
LDL aggregation. Five milliliters of the EDTA-plasma adjusted to a
density of 1.22 g/mL with solid KBr (0.326 g/mL) was layered on the
bottom of a centrifuge tube. Then, 5 mL EDTA-containing sodium
chloride solution (density 1.006 g/mL) was overlaid on the top of the
plasma. Ultracentrifugation was run at 350,000 g for 2 h at 4 °C, in a
Himac CP80MX ultracentrifuge. LDL particles were collected by the
aspiration of the yellow/orange band at the center of the saline layer and
dialyzed exhaustively overnight at 4 °C with 10 mM phosphate buffer
(pH 7.4). Protein concentration in LDL solution was determined by
Lowry's method (Lowry et al., 1951). The purity of LDL preparation wasN N
H N
H
N
O S
H
Fig. 1. Chemical structure of IBTC.veriﬁed by agarose gel electrophoresis (N98%). Isolated LDL was stored
at−20 °C for no longer than 2 weeks.
LDL oxidation
Conjugated dienes and TBARS formation
LDL samples (50 μg protein/mL) were pre-incubated at 37 °C in a
medium containing 10 mM phosphate buffer (pH 7.4) and different
IBTC concentrations (see ﬁgure legends). After 5 min, the oxidation
was initiated by the addition of CuSO4 (5 μM) or 2,2-azobis(2-
amidinopropane dihydrochloride) (AAPH) (1 mM). The oxidation
was monitored by measuring the increase in absorbance at 234 nm
due to conjugated diene (CD) formation as previously described
(Esterbauer et al., 1989). Aliquots were also removed at different time
points for evaluating thiobarbituric acid reactive substances (TBARS)
production as previously described (Ohkawa et al., 1979).
Determination of lag phase and maximum oxidation rate
In the studies of CD formation, there are several parameters which
can be obtained from diene vs. time proﬁles. The value of the lag phase
is commonly determined graphically by the intercept of the tangents
to the slow and fast increase of the diene absorption. Another
parameter is the maximum oxidation rate, given by the peak of the
ﬁrst derivative, i.e., change of A234 as a function of time (Gieseg and
Esterbauer, 1994). These parameters were calculated for CD formation
on LDL, using IBTC and also commonly used antioxidants compounds
as Vitamin C, Vitamin E (Duthie and Bellizzi, 1999), Quercetin
(Cushnie and Lamb, 2005; Hanasaki et al., 1994) and Resveratrol
(Kimura et al., 1983; Pace-Asciak et al., 1996) at the same con-
centrations as the ones used for IBTC. EC50 for lag phase or maxi-
mum CD formation for IBTC and for these antioxidants compounds
was obtained in order to compare the antioxidant activity of these
compounds versus IBTC.
Measurement of LDL-tryptophan ﬂuorescence
The ﬂuorescence spectra of native LDL display a single band cen-
tered at approximately 332 nm, which is assigned to the tryptophan
(Trp) residues in ApoB-100 (Giessauf et al., 1995). Loss of tryptophan
ﬂuorescence is a marker for oxidations at the protein core of LDL
(Giessauf et al., 1995; Reyftmann et al., 1990). Tryptophan (Trp)
ﬂuorescence was measured in a solution of LDL (50 μg protein/mL) in
PBS (10 mM), pH 7.4 at 37 °C, using a Shimadzu espectroﬂuorometer
(excitation at 282 nm and emission at 331 nm) (Giessauf et al., 1995;
Reyftmann et al., 1990). The kinetics of LDL oxidation was followed by
measuring the decrease of Trp-ﬂuorescence, corresponding to the
decomposition of this amino acid, after the addition of 5 μM CuSO4 in
the absence or presence of IBTC. The cuvettes had to be removed from
the excitation light between the single measurements to avoid
photooxidation of the tryptophan residues; ﬂuorescence was mea-
sured every 20 min. Data are shown as percentage of the decrease of
Trp ﬂuorescence in each sample. The time required for reaching half
Trp ﬂuorescence (t1/2) was calculated.
Serum oxidation
Venous blood was drawn from nonfasted healthy normolipidemic
voluntary donors into tubes containing no anticoagulant and cen-
trifuged at 1000 g for 15 min. Serum diluted 100-fold was incubated
at 37 °C in a medium containing 10 mM phosphate buffer (pH 7.4)
and different IBTC concentrations (see ﬁgure legends). The oxidation
was initiated by the addition of CuSO4 (30 μM) and CD formation was
monitored at 245 nm as previously described (Schnitzer et al., 1998).
Plasma oxidation
Venous blood was drawn from nonfasted healthy normolipi-
demic voluntary donors into tubes containing anticoagulant (sodi-
um citrate) and centrifuged at 1000 g for 15 min. Plasma was
22 R.P. Barcelos et al. / Life Sciences 89 (2011) 20–28removed and immediately used in the oxidation assays. Brieﬂy,
plasma samples were diluted 1:4 in 10 mM potassium phosphate
buffer, pH 7.4 and incubated at 37 °C with CuSO4 (100 μM) (de Bem
et al., 2008) and/or IBTC (1–20 μM). The total volume was 9 mL. At
different time points, aliquots (200 μL) were removed to evaluate
TBARS levels. Serum TBARS levels were determined based on
Ohkawa et al. (1979).Total reactive antioxidant potential (TRAP) assay
TRAP was determined by measuring the intensity of luminol
chemiluminescence induced by AAPH thermolysis in a luminometer
BioTek Synergy 2 (Lissi et al., 1992). The reaction mixture contained
300 μL of 10 mM AAPH and 10 μL of 1 mM luminol dissolved in 0.1 M
glycine buffer (pH 8.6). Incubation of this mixture produces a nearly
constant light intensity at room temperature after stabilization. IBTC
was added at different concentrations to determine the TRAP activity.
At this point, the intensity of luminescence is practically abolished. As
time goes by there is loss of antioxidant capacity of IBTC and the0 50 100 150 200
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Fig. 2. Effect of IBTC on conjugated dienes formation. LDL was incubated in the presence of Cu
incubationmediumwithout (1) or with 0.1 μM(2), 0.25 μM(3), 0.5 μM(4), 0.75 μM(5) or 1 μ
formation in isolated human LDL. [C] Representative ﬁgure of the dienes formation. The inc
10 μM (6) of IBTC and AAPH. [D] Effect of IBTC on lag phase values for conjugated diene
independent experiments in duplicate. Conjugated dienes were measured by determining th
time assay. Dotted line represents the control without CuSO4/AAPH and IBTC. * indicates st
CuSO4 group (pb0.05).luminescence intensity returns to the initial values. The area under
the curve (AUC) was evaluated for each IBTC concentration and
compared to vehicle AUC (Dresch et al., 2009).Lipid peroxidation assay
Lipid peroxidation was determined by measuring TBARS as
described by Ohkawa et al. (1979) from liver, kidney and brain
homogenates. Aliquots of 200 μL of liver, kidney and brain homoge-
nates were mixed to incubating medium containing Tris–HCl
(0.01 mM), IBTC at indicated concentrations (see ﬁgure legends)
and the oxidant sodium nitroprusside (SNP) 5 μMwas added in order
to start the reaction, then it was incubated at 37 °C for 60 min. The
reaction was stopped by adding 0.5 mL of acetic acid buffer, and lipid
peroxidation products were measured by the addition of 0.5 mL of
Thiobarbituric Acid (TBA) 0.6%. Tubes were then incubated in boiling
water for 60 min before spectrophotometric analysis. TBARS levels
were measured at 532 nm using a standard curve of Malondialdehyde
(MDA). Considering the variation in the tissues response to SNP and0
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Table 3
Effect of IBTC, Vitamin C, Vitamin E, Quercetin and Resveratrol on the lag phase and
maximum formation for conjugated dienes formation in human LDL.
EC50 (μM)
Lag phase Max formation
CuSO4 5 μM AAPH 1 mM
IBTC 0.345±0.018 9.687±0.503
Vitamin C 0.303±0.022⁎ 15.9±2.35
Vitamin E N1 N20
Quercetin 0.279±0.003⁎ 17.8±3.82
Resveratrol N1 N20
LDL was oxidized in the presence of CuSO4 5 μM or AAPH 1 mM. The values are
expressed as mean±S.D. for EC50 of four independent experiments in duplicate.
⁎ Indicates statistically difference from IBTC group (pb0.05).
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Table 1
Effect of IBTC on the oxidation rate for conjugated dienes formation in human LDL.
Conjugated dienes
Oxidation rate (Δabs/20 min)
Control ND
CuSO4 5 μM 0.182±0.0131
0.1 μM 0.166±0.049
0.25 μM 0.164±0.0381
0.5 μM 0.157±0.0106
0.75 μM ND
1 μM ND
LDL was oxidized in the presence of CuSO4 5 μM, and different concentrations of IBTC.
The values are expressed as mean±S.D. of four independent experiments in duplicate.
ND: not determined.
23R.P. Barcelos et al. / Life Sciences 89 (2011) 20–28IBTC, the results are presented as the variation of induced lipid
peroxidation in the different groups as compared to the variation in
the control group (Δ% Control) as described below:
A = B−C ð1Þ
This equation indicates the levels of MDA produced by SNP-
induction without IBTC in the different tissues tested. Where:
A nmol MDA/mg of protein induced by SNP
B nmol MDA/mg of protein in the presence of SNP (Control
induced Group)
C nmol MDA/mg of protein without SNP (General control
group)
The A value obtained was considered as the maximum level on
MDA produced by SNP for each tissue and group tested without IBTC.
D = E−F ð2Þ
This equation indicates the levels of MDA produced by SNP in the
presence of different IBTC concentrations in the different tissues
tested. Where:
D nmol MDA/mg of protein induced by SNP in the presence of
IBTC.
E nmol MDA/mg of protein induced by SNP in the presence of
IBTC.
F nmol of MDA/mg of protein with IBTC and without SNP.
The D value obtained was considered as the maximum level of
MDA produced by SNP for each group tested in the presence of IBTC.
Δ% Control = D × 100ð Þ= A ð3ÞTable 2
Effect of IBTC on the oxidation rate for conjugated dienes formation in human LDL.
Conjugated dienes
Oxidation rate (Δabs/20 min)
Control ND
AAPH 1 mM 0.0677±0.0038
0.1 μM 0.074±0.0044
0.5 μM 0.0727±0.0031
1 μM 0.0807±0.0067
5 μM 0.0643±0.0025
10 μM 0.034±0.0057⁎
LDL was oxidized in the presence of AAPH 1 mM, and different concentrations of IBTC.
The values are expressed as mean±S.D. of four independent experiments in duplicate.
ND: not determined.
⁎ Indicates statistically difference from AAPH group (pb0.05).Chelating activity of IBTC
The copper chelating capacity of IBTC was assessed by spectral
shifts produced when copper ions were incubated with the test
compound as described by Turchi et al.(2009). The reaction mixture
consisted of 2 mL of phosphate buffer saline (PBS, 10 mM, pH 7.4),
20 μL of IBTC solution (in DMSO, ﬁnal concentration of 37.5, 75, 150
and 300 μM) and 50 μL of CuSO4 solution (in distilled water, ﬁnal
concentration 150 μM). Spectra (200–600 nm) were recorded imme-
diately after preparing the mixtures and again after 15 min, in the
presence and absence of copper ions.
Aortic slices viability
Adult Wistar rats were decapitated, thoracic aorta were quickly
dissected and then removed, rinsed and submerged in a petri dish
ﬁlled with ice-cold isosmotic phosphate buffer (NaCl 124 mM,
Na2HPO4 10 mM, NaH2PO4 5 mM, KH2PO4 5 mM, glucose 10 mM,
pH 7.4) and cleaned of adherent fat and connective tissue in an ice-
bath (de Bem et al., 2008). Slices were normalized by weight and
incubated with IBTC concentrations (1–100 μM). After 30 min slices
were washed three times with isosmotic phosphate buffer. Immedi-
ately after incubation with treatments, slices were assayed by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test
for 30 min (37 °C) (Cordova et al., 2004). After incubation, aorta slices
were washed with isosmotic phosphate buffer three times (pH 7.4).
MTT is converted into a purple formazan after cleavage of the
tetrazolium ring by mitochondrial dehydrogenases. Formazan was
dissolved by the addition of DMSO, resulting in a colored compound100
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Fig. 3. Effect of different IBTC concentrations on decreased Trp ﬂuorescence mediated
by CuSO4. LDL was incubated in PBS with 5 μM CuSO4. The incubation medium without
IBTC (1) or with 0.1 μM (2), 0.25 μM (3), 0.5 μM (4), 0.75 μM (5) or 1 μM (6) of IBTC.
Fluorescence (Ex/Em=282/331 nm) was measured at intervals of 20 min at 37 °C.
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Fig. 5. Effect of IBTC on conjugated dienes formation in serum induced by copper. Serum
(diluted 100-fold) was incubated in presence of CuSO4. [A] Representative ﬁgure of the
dienes formation. The incubation medium without (1) or with 0.1 μM (2), 0.25 μM (3),
0.5 μM (4), 0.75 μM (5) or 1 μM (6) of IBTC. [B] The effect of IBTC on lag phase values for
conjugated dienes formation in isolated human LDL. Conjugated dienes were measured
by determining the absorbance at 245 nm every 20 min. The values are expressed as
mean±SEM of six independent experiments in duplicate. “N180 min” indicates a lag
phase higher than the time assay. Dotted line represents the control without CuSO4
and/or IBTC.* indicates statistical difference from control group (pb0.05). # indicates
statistical difference from CuSO4 group (pb0.05).
Table 4
Effect of IBTC on the oxidation t1/2 values for Trp ﬂuorescence in human LDL.
T1/2 Trp ﬂuorescence
Mean±S.D. (min)
CuSO4 5 μM 123.565±8.995
0.1 μM 131.217±9.409
0.25 μM 144.593±13.943
0.5 μM N180⁎
0.75 μM N180⁎
1 μM N180⁎
LDL was oxidized in the presence of CuSO4 5 μM, and different concentrations of IBTC.
The values are expressed as mean±S.D. of four independent experiments in duplicate.
“N180 min” indicates a lag phase higher than the time assay.
⁎ Indicates statistically difference from CuSO4 group (pb0.05).
24 R.P. Barcelos et al. / Life Sciences 89 (2011) 20–28whose optical density, following by a centrifugation for 1000 g for
5 min, the supernatants were read at 570 nmwith spectrophotometer
(Liu et al., 1997). This data are expressed as ABS/mg of tissue.
Statistical analysis
Data are expressed as means±SEM. Statistical analysis was
performed using a one-way and two-way analysis of variance
(ANOVA), followed by Student–Newman–Keuls test when appropri-
ate. In addition, linear regression was performed to identify a possible
dose dependent effect. Values of pb0.05 were considered signiﬁcant.
Results
Effect of IBTC on LDL oxidation
Conjugated diene formation in LDL
The formation conjugated dienes (CDs) during Cu2+-induced LDL
oxidation was signiﬁcantly reduced when IBTC was added at all
concentrations tested (pb0.05, Fig. 2A) (IC50=0.46±0.006 μM).
This formation is also shown in Fig. 2B, where the IBTC caused a
concentration-dependent increase of the lag phase of CDs formation
(r2=0.967, pb0.001). The oxidation rate was not signiﬁcantly
different at any concentration of IBTC (Table 1).
When AAPH was used as an oxidation reagent, the formation of
CDs was signiﬁcantly reduced only at the two highest concentrations
of IBTC (Fig. 2C) (IC50=0.60±0.012 μM). IBTC caused a concentra-0 90 18
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Fig. 4. Effect of IBTC concentrations on time-dependent changes in TBARS production
during LDL oxidation induced by CuSO4. LDL was incubated at 37 °C in the presence of
5 μM CuSO4. Data are expressed as mean±SEM of four experiments in duplicate. The
values are expressed by nmol MDA/20 μg of LDL. Numbers in the legends indicate the
IBTC concentration in μM. * indicates statistical difference from CuSO4 group (pb0.001).tion-dependent increase in the lag phase at higher concentrations of
−5 μM and 10 μM—(r2=0.908, pb0.001) (Fig. 2D). The oxidation
rate was signiﬁcantly reduced at 10 μM IBTC (pb0.05, Table 2).Table 5
Effect of IBTC on the oxidation rate for conjugated dienes formation in human serum.
Conjugated dienes
Oxidation rate (Δabs/20 min)
Control ND
CuSO4 30 μM 0.0692±0.0176
0.1 μM 0.061±0.0148
0.25 μM 0.0634±0.0197
0.5 μM 0.065±0.0116
0.75 μM 0.06±0.0112
1 μM ND
LDL was oxidized in the presence of CuSO4 30 μM, and different concentrations of IBTC.
The values are expressed as mean±S.D. of six independent experiments in duplicate.
ND: not determined.
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during plasma oxidation. Plasma (diluted 1:4) was incubated at 37 °C in the presence of
100 μMCuSO4. Data are expressed as mean±SEM of four experiments in duplicate. The
values are expressed by nmol MDA/mL. Numbers in legends indicate the IBTC
concentration in μM. * indicates statistical difference from CuSO4 group (pb0.001).
25R.P. Barcelos et al. / Life Sciences 89 (2011) 20–28IBTC was compared with other antioxidants to determine if the
effects of IBTC on the EC50 for the CD lag phase and the maximum CD
formation were similar to those of naturally occurring popular
antioxidants. The EC50 for IBTC was signiﬁcantly higher than the
EC50 values for quercetin or vitamin C, when studied for the CD lag
phase in Cu2+-induced LDL oxidation. However, there were no
signiﬁcant differences in EC 50 values among IBTC, vitamin C, and
quercetin for themaximum formation of CD in AAPH-induced LDL. The
EC50 values for vitamin E and resveratrol could not be determined in
our experimental protocol (Table 3).
Effect of IBTC on LDL tryptophan ﬂuorescence
The loss of tryptophan (Trp) ﬂuorescence in LDL during the Cu2+-
induced LDL oxidation is shown in Fig. 3. When LDL was incubated
with different concentrations of IBTC, there was a signiﬁcant increase
in t1/2 of Trp at the three highest IBTC concentrations (0.5, 0.75 and
1 μM, Table 4), prolonging it to N180 min.
Effect of IBTC on TBARS formation in LDL
TBARS formation in LDL is shown in Fig. 4. In the presence of IBTC
at concentrations of 0.25, 0.5, 0.75, and 1 μM, TBARS formation was
signiﬁcantly reduced compared to CuSO4 (5 μM) during a 90 min time
course of LDL oxidation (pb0.001). When the time course of Cu2+-
induced LDL oxidation reached 180 min, IBTC at concentrations of 0.5,
0.75, and 1 μM signiﬁcantly reduced TBARS formation (pb0.001).Co
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Fig. 7. Effect of IBTC on total radical-trapping antioxidant potential (TRAP). Columns
represent mean±SEM of four experiments in duplicate. The values are expressed by
AUC. * indicates statistical difference from control group (pb0.001).Effect of IBTC on blood oxidation
Conjugated diene formation in serum oxidation. Fig. 5A shows the
formation of CDs in serum using 30 μM CuSO4 as the oxidation agent.
The CD formation was signiﬁcantly reduced (pb0.05) when IBTC was
added to all tested concentrations (IC50=0.46,±0.013 μM). The
compound caused an increase in the CD lag phase in a concentration-
dependent manner (r2=0.958, pb0.001, Fig. 5B). The oxidation rates
were the same among different groups (Table 5).
Effect of IBTC on TBARS formation from plasma oxidation
Fig. 6 shows TBARS formation from Cu2+-induced plasma
oxidation. IBTC (1, 5, 10, and 20 μM) signiﬁcantly reduced TBARS
formation at 90 min compared to 100 μM CuSO4 (pb0.001). At
180 min of Cu2+-induced plasma oxidation, IBTC (5, 10, and 20 μM)
signiﬁcantly reduced TBARS formation (pb0.001).Fig. 8. Effect of IBTC on liver [A] kidney [B] and brain [C] homogenates on TBARS
production. 5 μM Sodium nitroprusside (SNP) was used as oxidant to induce TBARS
production. TBARS are expressed as Δ% Control (induced−basal). The values are
expressed as mean±SEM of four independent experiments in duplicate. Dotted line
represents the control group (100% induced). * indicates statistical difference from
control group (pb0.001).
co
ntr
ol
1u
M
5u
M
10
uM
50
uM
10
0u
M
0
2000
4000
6000
A
bs
/m
g 
of
 ti
ss
ue
Fig. 9. Aortic slices viability. Aortic slices were incubated in presence of IBTC (1, 5, 10, 50
and 100 μM), and viability was measured by MTT assay. The data are expressed as ABS/
mg of tissue. The values are mean±SEM of six independent experiments in duplicate
(pb0.05).
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Fig. 7 shows the antioxidant potential of IBTC when AAPH was
used as an oxidizing agent. Concentrations of IBTC ranging from 10 to
20 μM showed a signiﬁcant effect on total radical-trapping antioxi-
dant potential. No chelating activity was detected between IBTC and
CuSO4 when they were incubated together (data not shown).
Effect of IBTC on SNP-induced lipid peroxidation in rat tissues
The TBARS formation induced by SNP (5 μM) in liver homogenate
is shown in Fig. 8A. IBTC signiﬁcantly reduced TBARS formation at 5
and 10 μM IBTC (pb0.001). In kidney (Fig. 8B) and brain (Fig. 8C)
homogenates, all IBTC concentrations signiﬁcantly reduced TBARS
formation induced by 5 μM SNP (pb0.001).
Aortic slices viability
Aortic slices in the presence of IBTC at concentrations of 1 to
100 μM did not show any changes in the MTT assays compared to
control, and there are no signiﬁcant differences among groups (Fig. 9)
(pb0.05).
Discussion
There are controversial studies concerning the use of antioxidants
as an alternative therapy for atherosclerotic prevention (Mashima
et al., 2001), and these conﬂicting ﬁndings may reﬂect our limited
understanding about the LDL oxidation process in atherogenesis and
about how antioxidants protect from CVD. To investigate a possible
atheroprotective property of IBTC, and to provide knowledge re-
garding IBTC in this therapeutic strategy, we tested IBTC's antioxidant
properties in LDL and serum when they were exposed to different
oxidants. Our results showed that IBTC was able to reduce the
formation of CDs and increase the CD lag phase in concentration-
dependent manners when either AAPH or CuSO4 was used as the LDL
oxidizing agent. The results were similar when we tested IBTC in
human serum under the same conditions. There was an increase inN
O
NH
N N
S
H H
H2O2, 
OH•, H
Scheme 1. Possible IBTC ant1/2 of Trp ﬂuorescence of Cu2+-oxidized LDL in the presence of IBTC.
IBTC produced an interesting result in the TRAP assay, indicating its
role as a ROS scavenger. The TBARS formation in LDL and plasma was
reduced when IBTC was added to the reaction medium and SNP-
induced lipid peroxidation was also reduced when IBTC was present.
The assay of aortic slices viability showed that IBTC has no cytotoxicity
in aortic slices.
There is evidence suggesting that an elevated plasma copper
concentration is associated with existing atherosclerosis and repre-
sents a risk factor (Ferns et al., 1997). Catalytically active copper ion
has been found in gruel taken from human advanced atherosclerotic
lesions, indicating that the interior of these lesions is a highly oxi-
dative environment. Consequently, the use of copper ions to promote
peroxidation of LDL under in vitro conditions can be considered a
valid model to study events occurring in the atherosclerotic arterial
wall (Smith et al., 1992). In addition, we used AAPH, a hydroxyl
radical generator, which generates peroxyl radicals at a constant rate
in aqueous medium and induces the chain oxidation of human LDL by
a free radical mediated mechanism (de Bem et al., 2008). AAPH has
also been reported as a good alternative for mimicking oxidative
insults that occur to lipid and protein moieties of LDL during the
atherogenic process (Atkin et al., 2005). The study of CD formation in
LDL oxidized by copper is often used to characterize the atherogeni-
city of LDL or the therapeutic usefulness of antioxidants (Esterbauer
et al., 1989; Matsuura et al., 2008; Stocker and Keaney, 2004; Zolese
et al., 2005). The lag phase determination, which represents the
intrinsic resistance of LDL to oxidation, is widely used in studies to test
the activity of possible antiatherogenic compounds (Gieseg and
Esterbauer, 1994; Witztum, 1994). Furthermore, the protective effect
of IBTC against LDL oxidation can occur via several mechanisms, such
as (A) scavenging of peroxyl radicals, thus breaking the peroxidation
chain reaction, (B) chelating free Cu2+ to form redox-inactive
complexes and thus reducing metal-catalyzed oxidation of LDL, and
(C) inhibiting the binding of Cu2+ to apolipoproteins and subse-
quently preventing the modiﬁcation of amino acid-apoB protein
residues (Berrougui et al., 2006).
In our study, we observed that IBTC could prolong, in a
concentration-dependent manner, the lag phase in CD formation
when CuSO4 or AAPH were used as oxidizing agents. The increase in
the lag phase for copper-induced LDL oxidation by antioxidants has
already been described (Wen et al., 1999). Vitamin E, an endogenous
antioxidant, is known to prevent LDL oxidation by donating the
hydrogen atom of its phenolic hydroxyl group to a lipid peroxyl
radical (Meydani, 1995; Seppo et al., 2005). Vigna et al. (2003)
showed that the increase in the lag phase and the reduction of the
lipid peroxide formation are probably related to antioxidant pro-
perties or to mechanisms involving ion (Cu2+) chelation. Notably,
the reduction of CD formation by IBTC is clearly observed in Fig. 2A
and C (CuSO4 and AAPH-induced CD formation, respectively).
Considering that TRAP indirectly measures the content of non-
enzymatic antioxidant defenses (Lissi et al., 1995), our results
support the hypothesis that IBTC has ROS scavenging activity
(Fig. 7). Additionally, we clearly demonstrate that IBTC possesses
antioxidant activity in levels that could be compared to vitamin CN
O
NH
N N
+S
H H
O-
O2•, 
O2•
tioxidant mechanism.
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antioxidant molecule and its potential could be compared to other
naturally occurring antioxidants. Moreover, the concentration of
IBTC used in this study was much lower than the copper con-
centration, indicating that Cu2+ chelation could not be the likely
mechanism of IBTC. In fact, we did not detect Cu2+ chelating activity
by IBTC in our tests, even when using concentrations higher than
those for CuSO4 (data not shown). Based on our results, we believe
that IBTC produces its antioxidant activity via free radical scaveng-
ing rather than by chelating Cu2+.
Searching for modiﬁcations caused by IBTC in the protein moieties
of LDL, we observed that IBTC prevented the Cu2+-induced loss of Trp
ﬂuorescence in LDL. Intrinsic ApoB-100 ﬂuorescence has been widely
used to monitor protein oxidative damage in Cu2+-induced oxidized
LDL (de Lima Portella et al., 2008; Giessauf et al., 1995). It has been
reported that the ﬂuorescence spectrum of native LDL is associated
with Trp residues in apo-B, and Trp ﬂuorescence is a marker for
oxidation occurring at the protein core of LDL (Reyftmann et al.,
1990). Degeneration of Trp is an early event in Cu2+-mediated LDL
oxidation and plays an important role in initiating lipid oxidation in
the LDL particle (Giessauf et al., 1995). Apo-B is wrapped around the
outer surface of the LDL molecule with hydrophobic segments
immersed in the hydrocarbon chain region of the phospholipid
monolayer, making these hydrophobic domains more susceptible to
oxidative attack (Prassl et al., 1998). Thus, when the mechanism by
which LDL is oxidized is considered, some elements, including lipid–
apo-B interactions and physicochemical properties of LDL must be
considered, because they affect the oxidation behavior and conse-
quently the mechanism involved (Abuja et al., 1999; Prassl et al.,
1998). Considering this, our results show that IBTC exhibited a
protective effect on AAPH and Cu2+-induced Trp oxidation, corrob-
orating the hypotheses that IBTC may be acting as an antioxidant
molecule, thus avoiding the oxidation and degeneration of Trp in apo-
B.
Formation of lipid hydroperoxides in LDL is accepted as an early
event in LDL oxidation (Girotti, 1998), because these lipid hydroper-
oxides can up-regulate the uptake of LDL into the cells (Kawamura
et al., 1994). Remarkably, we showed that IBTC decreased TBARS
formation in human LDL at higher concentrations after 90 min
(partially oxidized-LDL) and 180 min (completely oxidized-LDL) of
incubation. According to this evidence, IBTC may interfere with LDL
oxidation by interacting with ApoB-100, thus avoiding lipid hydro-
peroxide oxidation. We suggest that the effect exerted by IBTC against
lipid peroxidation of human plasma LDL may be of pathophysiologic
relevance.
Spranger et al. (1998) suggested that LDL oxidation in vivo can be
more adequately tested in vitro using the whole plasma/serum,
because LDL in vivo occurs in the interstitial space of the arterial wall,
where it may be shielded from various antioxidants present in
plasma/serum (Schwartz et al., 1991; Witztum and Steinberg, 1991).
For this reason, we performed assays using serum in conditions
similar to the assays conducted using isolated LDL. Notably, the Cu2+-
induced CD formation was reduced and the lag phase was signif-
icantly increased in a concentration-dependent manner in the
presence of IBTC. When we tested TBARS formation in plasma, we
found the same result as that obtained using the isolated LDL.
Moreover, the IBTC protection from serum oxidation was greater than
the protection from LDL oxidation. This result could be due in part to
the presence of other antioxidants in plasma/serum (de Lima Portella
et al., 2008).
Besides, aortic slice viability assay using MTT indicates that IBTC
has no cytotoxic effect in aortic slices at the concentrations used in our
experiments, even using a concentration 100 times higher than the
effective concentrations used in our previous tests.
When IBTC was tested with tissue homogenates, we observed that
the compound reduced lipid peroxidation, as conﬁrmed by reducedlevels of TBARS. Different IBTC concentrations were required for an
effective decrease in TBARS production among the tissues tested. This
ﬁnding that may be related to different capacities of these tissues to
respond against an oxidizing agent (Puntel et al., 2009).
Taken together, results obtained in the present study strongly
indicate that IBTCmay be acting as an antioxidant molecule and, more
importantly, as an antiatherogenic agent as evidenced by results of
LDL oxidation assays. We hypothesize that the antioxidant activity
displayed by IBTC relies on its interaction with ROS. Scheme 1
demonstrates our suggested mechanism of action for IBTC. IBTC can
react with these ROSs generating its oxidized form (ox-IBTC) a
sulfoxide molecule formed in an environment rich in oxygen
molecules such as peroxides, hydroperoxides, or another oxygen
free radical species (Fraaije et al., 2004; Vannelli et al., 2002).
Conclusion
In conclusion, our results show that IBTC is capable of protecting
LDL and serum from oxidation caused by cooper and AAPH in vitro. In
addition, IBTC prevents lipid hydroperoxide formation and protects
Trp from oxidation. These ﬁndings clearly indicate a high potential for
IBTC to act as an antiatherogenicmolecule. Thus, this study shows that
thiosemicarbazones may exert atheroprotective activities; however,
further studies are needed to identify the exact molecular mecha-
nisms for this activity. Furthermore, IBTC shows an antioxidant
activity in homogenates of different tissues obtained from rats. These
results are in agreement with the data obtained with LDL and serum.
Therefore, we suggest that IBTC may be a useful compound to serve as
an antioxidant in other experimental paradigms that involve
oxidative damage in brain, liver, and kidney.
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